Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 23

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
 Market Offering

During March 2021, the Company entered into a
sales agreement (“Sales Agreement”) with BTIG, LLC (“BTIG”), as sales agent, to establish an At-The-Market (“ATM”)
offering program of up to $45 million of common stock, subject to certain limitations on the amount of common stock that may be offered
and sold by the Company set forth in the sales agreement. During August 2023, the Company and BTIG entered into Amendment No. 1 to the
Sales Agreement. The Company is required to pay BTIG a commission of 3% of the gross proceeds from the sale of shares. During the
nine months ended September 30, 2024, the Company issued and sold 198,364 shares of common stock at an average price of $10.56 per
share under the ATM program. The aggregate net proceeds were approximately $2.0 million after commission expenses.

During August 2024, the Company entered into an
amended and restated at-the-market sales agreement with RBC Capital Markets LLC and BTIG (together, the “Sales Agents”) relating
to the offer and sale of shares of our common stock with an aggregate offering price of up to $75.0 million. This amended and restated
at-the-market sales agreement replaced the Sales Agreement entered into with BTIG in March 2021, as amended in August 2023. The Company
is required to pay the Sales Agents a commission of 3% of the gross proceeds from the sale of shares. During the nine months
ended September 30, 2024, the Company issued and sold 48,762 shares of common stock at an average price of $6.96 per share
under the ATM program. The aggregate net proceeds were approximately $0.3 million after commission expenses. During the nine months
ended September 30, 2025, the Company issued and sold 1,304,707 shares of common stock at an average price of $8.01 per
share under the ATM program. The aggregate net proceeds were approximately $10.1 million after commission expenses. At September
30, 2025, the Company had $64.5 million of common stock available under the amended and restated at-the-market agreement.

During July 2023, the Company sold 75,697 shares of its common
stock at an average price of $10